C-XLI9FibroBiologics
fibroblast cell therapy, regenerative medicine, immune modulation
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-XLI9
C-XLI9C-XLI9fibroblast cell therapy, regenerative medicine, immune modulation
0-100 chain-logic scale · 15 dimensions · scored on public evidence
FibroBiologics fibroblast cell therapy, regenerative medicine, immune modulation
FibroBiologics is a clinical-stage biotechnology company focused on developing and commercializing fibroblast cell-based therapies for chronic diseases. Its proprietary fibroblast platform supports programs in degenerative disc disease, multiple sclerosis, wound healing, cancer, and anti-aging applications including thymic and splenic involution reversal. The company states that it holds more than 150 U.S. and international issued or pending patents across multiple clinical pathways.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
FibroBiologics — Translational · Bottom quartile. Derived deterministically from 16 extracted project(s). Most-advanced status: phase 2. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic